glutenases
Start with the article narrative. Use the right sidebar to jump from prose into concept context, nearby graph relationships, and source provenance.
A pill you take with meals that digests gluten before your immune system can see it — the most advanced non-dietary treatment class for celiac disease.
Glutenases are enzymes designed to break down prolamin peptides in the GI tract — specifically the proline-rich sequences that normal digestive enzymes cannot cleave. Taken orally before or with a meal, they would degrade immunogenic gliadin fragments into harmless amino acids before those fragments can cross the intestinal barrier and trigger an immune response.
The Problem They Solve
prolamins resist normal gut proteases because of their high proline content — proline creates rigid structures that block the protease active site. The most immunogenic fragment, the gliadin 33-mer, survives the entire digestive process intact. Glutenases introduce enzymes that specifically cleave proline-glutamine bonds (prolyl endopeptidases), completing what the gut cannot do on its own.
Key Candidates
Latiglutenase (ALV003)
- Combination of two enzymes: EP-B2 (from barley) + SC-PEP (bacterial prolyl endopeptidase)
- In a 2014 phase 2 gluten-challenge trial, it attenuated mucosal injury and IEL expansion during daily 2 g gluten exposure, but did not significantly change symptoms over 6 weeks
- Later larger real-world trial was negative
- Phase 3 development status uncertain
TAK-062 / Kuma030 (Takeda)
- An engineered acid-active synthetic glutenase with high specificity for immunodominant gliadin epitopes
- Designed to operate at the acidic pH of the stomach — degrading gluten before it reaches the intestine
- In Phase 2 development
AN-PEP (Aspergillus niger prolyl endoprotease)
- A fungal prolyl endopeptidase active at acidic gastric pH
- Available OTC in some markets as a dietary supplement
- Clinical evidence for efficacy in celiac disease is limited; marketed more for NCGS-level protection
Endoproptease-40
- Earlier-stage candidate
A broader 2026 beyond-GFD review supports the same overall picture: latiglutenase remains one of the best-studied enzyme candidates, but trial results have been mixed. The review highlights a recurring pattern in which biologic or subgroup signals look more encouraging than uniform symptom success across broad celiac populations.
Limitations
Glutenases are designed as adjuncts to GFD, not replacements. A 2024 therapy-landscape review makes the likely use-case especially clear: these drugs are mainly intended to protect against inadvertent exposure, restaurant/cafeteria risk, travel, and other real-world contamination problems rather than to permit normal gluten eating. Key limitations:
- They cannot handle large amounts of gluten (a meal of bread, not just accidental exposure)
- Efficacy depends on acting before gluten crosses the epithelial barrier — timing and dosing are critical
- They don't address the HLA/T cell sensitisation that already exists — the immune response is primed and waiting
The realistic use case is protection against inadvertent gluten exposure (restaurant meals, cross-contamination), not intentional gluten consumption. A second 2024 perspective reinforces that this adjunctive framing is also likely to be how regulators think about early approved therapies: as support for carefully defined patient subgroups, not as a general license to relax the diet.
Comparison to Other Approaches
| Approach | Where It Acts | What It Addresses |
|---|---|---|
| Glutenases | GI lumen (before absorption) | Degrades trigger |
| Larazotide | Epithelial barrier | Reduces gluten crossing |
| IL-15 inhibitors | Immune system | Suppresses innate response |
| Tolerance induction | Adaptive immune memory | Trains T cells to ignore gluten |
Related Concepts
prolamins | gliadin | tight-junctions | larazotide-acetate | gluten-free-diet | il-15-inhibitors | tolerance-induction
Source Basis
Current synthesis incorporates:
raw/nutrients-12-02095.pdf— Gluten Degrading Enzymes for Treatment of Celiac Disease (2020)raw/PIIS001650851400242X.pdf— Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac Disease (2014)
The first is a review-level treatment landscape source; the second is a primary clinical trial focused on ALV003/latiglutenase.
This page also now draws on:
raw/PIIS0016508524004165.pdf(How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet, 2024), which reframes glutenases as practical contamination-buffer therapies rather than true diet replacementsraw/biomedicines-14-00029-v2.pdf(Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet, 2026), which is useful for the later mixed-trial context around latiglutenase and the broader enzyme-class landscaperaw/cogas-41-124.pdf(New therapies in celiac disease, 2025), which updates the enzyme-therapy picture around latiglutenase and TAK-062/Kuma030 while keeping the adjunct-to-GFD framing